Viewing Study NCT01300156


Ignite Creation Date: 2025-12-24 @ 11:37 PM
Ignite Modification Date: 2025-12-25 @ 9:27 PM
Study NCT ID: NCT01300156
Status: UNKNOWN
Last Update Posted: 2011-02-21
First Post: 2011-02-18
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOx) for Refractory or Relapsed Hodgkin's Lymphoma (HL)
Sponsor: National Cancer Center, Korea
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module